Winthrop Capital Management’s AbbVie ABBV Stock Holding History

Winthrop Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$936K	Buy	4,303 +87	+2%	+$19.3K	0.24%	68
2025 Q4	$963K	Sell	4,216 -101	-2%	-$23K	0.22%	70
2025 Q3	$1M	Buy	4,317 +70	+2%	+$14.3K	0.24%	68
2025 Q2	$788K	Buy	4,247 +1,615	+61%	+$300K	0.2%	79
2025 Q1	$551K	Hold	2,632	–	–	0.15%	92
2024 Q4	$464K	Buy	2,632 +5	+0.2%	+$919	0.12%	96
2024 Q3	$519K	Hold	2,627	–	–	0.25%	46
2024 Q2	$451K	Buy	2,627 +59	+2%	+$9.77K	0.23%	46
2024 Q1	$468K	Buy	2,568 +56	+2%	+$9.65K	0.22%	50
2023 Q4	$389K	Buy	+2,512	New	+$366K	0.13%	99

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Winthrop Capital Management's ABBV Position: Q1 2026 in Review

Winthrop Capital Management increased its AbbVie (ABBV) stake by 2.1% in Q1 2026, buying an estimated $19.3K and bringing the position to 4,303 shares worth $936K. The position accounts for 0.24% of the portfolio, ranked #68.

Winthrop Capital Management first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $1M in Q3 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Winthrop Capital Management held 4,303 shares of AbbVie worth $936K as of Q1 2026.
Winthrop Capital Management bought 87 AbbVie shares in Q1 2026, an estimated $19.3K.
AbbVie made up 0.24% of Winthrop Capital Management's portfolio in Q1 2026, its #68 holding.
Winthrop Capital Management first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
Winthrop Capital Management's AbbVie position peaked at $1M in Q3 2025.
4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Winthrop Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.